Clinical trials: Colorectal Tumor
Colorectal Cancer, Adult
PIN in Combination With Sintilimab in Previously Treated pMMR/MSS CRC With Hepatic Metastases
In this single-center,open-label, phase I study, the safety and efficacy of PIN in combination with anti-programmed cell death -1 (anti-PD1) antibody therapeutic regimen (sintilimab) will be evaluated in patients with advanced…
- Trial name
- NCT07411781
- Testing
- PIN+sintilimab
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Chinese PLA General Hospital
Rectal Adenocarcinoma, High-Risk Cancer
NCT + PD1 + Ketogenic Diet and/or Vitamin C for LARC
To explore the efficacy and safety of adding a ketogenic diet and/or high-dose intravenous vitamin C to neoadjuvant short-course radiotherapy followed by mFOLFOX6 chemotherapy combined with serplulimab in patients with locally…
- Conditions
- Rectal Adenocarcinoma, High-Risk Cancer, MSS
- Trial name
- CRI-KEV (NCT07765667)
- Testing
- Short-Course Radiotherapy, PD-1 monoclonal antibody, mFOLFOX6 regimen
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Sixth Affiliated Hospital, Sun Yat-sen University
Carcinoma, Endometrial Adenocarcinoma
PEN-866 in Patients With Advanced Solid Malignancies
Protocol PEN-866-001 is an open-label, multi-center, first-in-human Phase 1/2a study evaluating PEN-866 in patients with advanced solid malignancies whose disease has progressed after treatment with previous anticancer therapies.
- Conditions
- Carcinoma, Endometrial Adenocarcinoma, Neoplasms, Squamous Cell Carcinoma of the Anus
- Trial name
- NCT03221400
- Testing
- PEN-866 Sodium, fluorouracil, Folinic acid
- Where
- 16 sites in United States
- Volunteers
- 340 people
- Sponsor
- Tarveda Therapeutics
Metastatic Colorectal Cancer
Prospective Observational Study of 1st and 2nd Line Vectibix® Use in RAS-wt mCRC Pts to Evaluate Pattern of Use and ORR
The study will shed additional light on the impact of Vectibix® under the current, standard clinical conditions of mCRC treatment in Greece.
- Trial name
- VISION (NCT02322736)
- Where
- 20 sites in Greece
- Volunteers
- 218 people
- Sponsor
- Amgen
Breast Cancer, Colon Cancer
The Efficacy of Health Partnership Program for Cancer Patients
The Objectives of this study is 1. To evaluate the efficacy for exercise, diet, and posttraumatic growth as a result of participating in tailored program (Health Partnership Program) for 24 weeks 2.
- Conditions
- Breast Cancer, Colon Cancer, Gastric Cancer, Lung Cancer
- Trial name
- NCT01527409
- Testing
- Tailored health partnership program, Usual care and health education workshop
- Where
- 10 sites in South Korea
- Volunteers
- 248 people, healthy volunteers welcome
- Sponsor
- National Cancer Center, Korea
Colon Cancer
Impact of Exercise and Hyperlipidic Meal on Free Circulating DNA in Patients With Metastatic Colonic Cancer and Healthy Subjects
The study of circulating tumoral DNA makes it possible to study, without invasive procedures or pathological studies, the tumoral DNA circulating in the blood of a patient and its various alterations.
- Trial name
- ASRHACOLS (NCT05147545)
- Testing
- Moderate intensity physical effort, Low intensity physical effort, Hyperlipidic meal
- Where
- France
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Colon Cancer
Robotic-assisted Left Hemicolectomy for Left Colon Cancer
The main goal of this study is to clarify if Robotic-assisted surgery could become the standard approach in patients undergoing left colonic resection.
- Trial name
- RALH (NCT03696472)
- Testing
- robotic assisted surgery, laparoscopic
- Where
- China
- Volunteers
- 2 people, healthy volunteers welcome
- Sponsor
- Southwest Hospital, China
Colorectal Cancer, Metastatic Cancer
Surgery With or Without Radiofrequency Ablation Followed by Irinotecan in Treating Patients With Colorectal Cancer That is Metastatic to the Liver
RATIONALE: Radiofrequency ablation uses high-frequency electric current to kill tumor cells. Combining radiofrequency ablation with surgery may kill more tumor cells.
- Trial name
- NCT00030563
- Testing
- irinotecan hydrochloride, adjuvant therapy, conventional surgery
- Where
- 3 sites in United States, Canada
- Sponsor
- University of Washington
Natural Killer Cell Cytokine Production
Measurement of NK Cell Activity in Whole Blood in Subjects Being Screened for Colorectal Cancer Using Colonoscopy
This study will look at measuring the activity of natural killer (NK) cells using the in vitro diagnostic device NK Vue in subjects being screened for colorectal cancer using colonoscopy.
- Trial name
- NCT02291198
- Testing
- NK Vue: NK cell activity in stimulated whole blood
- Where
- Canada
- Volunteers
- 1,081 people, healthy volunteers welcome
- Sponsor
- ATGen Canada Inc
Colorectal Cancer, Non Small Cell Lung Cancer
Circulating DNA to Improve Outcome of Oncology PatiEnt. A Randomized Study
COPE is a biology driven protocol with 2 independent, multicentric, two-arm non-comparative randomized (2:1) phase II trials in 2 distinct populations: colorectal cancer patients and non-small-lung cancer patients.
- Trial name
- COPE (NCT04258137)
- Testing
- Liquid biopsy
- Where
- 6 sites in France
- Volunteers
- 332 people
- Sponsor
- Institut Bergonié
Colorectal Cancer
Comparative Effectiveness of Split-Dose Colonoscopy Bowel Preparation Regimens
From the patients' perspective, the most formidable part of the colonoscopy experience is the process of bowel cleansing. A poorly tolerated bowel preparation regimen often leads to incompletion of scheduled colonoscopies which…
- Trial name
- NCT03298945
- Testing
- Miralax-Gatorade Prep, Golytely
- Where
- United States
- Volunteers
- 2,239 people
- Sponsor
- VA Office of Research and Development
Colorectal Cancer, Pancreatic Cancer
KRAS Neoantigen Nanovaccine as Adjuvant Therapy for Colorectal Cancer/Pancreatic Cancer
This clinical trial will utilize a neoantigen nanovaccine constructed from the bacterial membranes of an engineered Lactococcus lactis strain (FOLactis).
- Trial name
- NCT07353645
- Testing
- KRAS Neoantigen Nanovaccine
- Where
- China
- Volunteers
- 49 people
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Advanced or Metastatic KRAS-mutant Tumor in Pancreatic Adenocarcinoma, Advanced or Metastatic KRAS-mutant Tumor in Colorectal Cancer
Phase 1/2a Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of WEF-001 as Monotherapy in Advanced KRAS-Mutant Solid Tumours.
This is a study designed to assess the safety, tolerability, pharmacokinetics and preliminary efficacy of WEF-001 as monotherapy in patients with Advanced KRAS-mutant solid tumours.
- Conditions
- Advanced or Metastatic KRAS-mutant Tumor in Pancreatic Adenocarcinoma, Advanced or Metastatic KRAS-mutant Tumor in Colorectal Cancer, Advanced or Metastatic KRAS-mutant Tumor in Non Small Cell Lung Cancer, Advanced Solid Tumors
- Trial name
- NCT07148128
- Testing
- WEF-001
- Where
- 4 sites in United States, Canada and 1 more
- Volunteers
- 110 people
- Sponsor
- Auricula Biosciences Inc.
ctDNA, Chemotherapy
Randomized Study of Plasma ctDNA Methylation to Guide Adjuvant Chemotherapy Decisions in High-Risk T3N0 Colorectal Cancer
This study will utilize ctDNA methylation detection to evaluate patients with high-risk T3N0 stage II colorectal cancer who are ctDNA-positive one month after surgery.
- Conditions
- ctDNA, Chemotherapy, Colorectal Cancer
- Trial name
- CLEAR-02 (NCT07562711)
- Testing
- Capecitabine, FOLFOX (5-fluorouracil, Leucovorin, Oxaliplatin)
- Where
- China
- Volunteers
- 340 people
- Sponsor
- Fudan University
Rectal Cancer
Preoperative IMRT With Concurrent High-dose Vitamin C and mFOLFOX6 in Locally Advanced Rectal Cancer
The purpose of this study is to evaluate the safety and efficacy of preoperative chemoradiotherapy (IMRT) with concurrent high-dose intravenous vitamin C and mFOLFOX6 in locally advanced rectal cancer patients.
- Trial name
- CORT (NCT04801511)
- Testing
- Vitamin C
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Zhou Fuxiang
Colorectal Cancer
Computerized Tomographic Colonography Compared With Standard Diagnostic Procedures in Detecting Colorectal Neoplasia
RATIONALE: New diagnostic procedures such as computed tomographic colonography may provide a less invasive method of identifying patients who have colorectal neoplasia.
- Trial name
- ACRIN 6656 (NCT00005809)
- Testing
- computed tomography, diagnostic colonoscopy
- Where
- 11 sites in United States
- Sponsor
- American College of Radiology Imaging Network
Colon Cancer
Adjuvant Colon Cancer w/ ELOXatin®/5 FU Based Regimen: ACCELOX
Adjuvant Colon Cancer With ELOXatin®/5 FU Based Regimen: ACCELOX
- Trial name
- NCT01310972
- Testing
- Registry
- Where
- Saudi Arabia
- Volunteers
- 6 people
- Sponsor
- King Faisal Specialist Hospital & Research Center
Oropharynx Cancer, Oral Cavity
Oncology, Undernutrition and Sensoriality: Links, Mechanisms and Levers for Action
Cancers of the upper aerodigestive tract account for around 4% of all malignant tumours worldwide. Colon and liver cancer are the most common digestive cancers.
- Conditions
- Oropharynx Cancer, Oral Cavity, Colon Cancer, Liver Cancer
- Trial name
- ONDES (NCT06600295)
- Testing
- tests/questionnaires, biological samples, evaluation
- Where
- France
- Volunteers
- 306 people
- Sponsor
- Centre Hospitalier Universitaire Dijon
Colorectal Cancer Stage IV
Intermittent or Continuous Panitumumab Plus FOLFIRI for RAS/B-RAF Wild-type Metastatic Colorectal Cancer
The investigators hypothesize that intermittent first-line Panitumumab plus FOLFIRI is effective as the same regimen given continuously, in unresectable metastatic RAS and BRAF wild type colorectal cancer patients.
- Trial name
- IMPROVE (NCT04425239)
- Testing
- Panitumumab
- Where
- Italy
- Volunteers
- 151 people
- Sponsor
- National Cancer Institute, Naples
Colorectal Neoplasms, Microsatellite Instability
Pembrolizumab in MMR-Proficient Metastatic Colorectal Cancer Pharmacologically Primed to Trigger Hypermutation Status
In this study, MMRd metastatic colorectal cancer (mCRC) patients who failed standard therapies will undergo treatment with pembrolizumab, while RAS-extended mutated MMR-proficient mCRC patients will be tested for…
- Trial name
- ARETHUSA (NCT03519412)
- Testing
- temozolomide (induction),, pembrolizumab (treatment)
- Where
- 4 sites in Italy
- Volunteers
- 107 people
- Sponsor
- IFOM ETS - The AIRC Institute of Molecular Oncology
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.